2006
DOI: 10.1007/s10637-006-5730-2
|View full text |Cite
|
Sign up to set email alerts
|

SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group

Abstract: SarCNU is inactive in recurrent or metastatic colorectal patients who have progressed after first-line chemotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2008
2008
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 10 publications
0
3
0
Order By: Relevance
“…46 Although SarCNU showed better efficacy than carmustine against gliomas, 47,48 it caused severe pulmonary toxicity in phase II trials and is not approved by the U.S. FDA. 49,50 Other compounds, including ranimustine 23, nimustine 24, and fotemustine 25, are approved to be used in Japan, Japan/China, and Europe, respectively. However, they have not gained approval from the U.S. FDA.…”
Section: Nitrogen Mustardsmentioning
confidence: 99%
See 1 more Smart Citation
“…46 Although SarCNU showed better efficacy than carmustine against gliomas, 47,48 it caused severe pulmonary toxicity in phase II trials and is not approved by the U.S. FDA. 49,50 Other compounds, including ranimustine 23, nimustine 24, and fotemustine 25, are approved to be used in Japan, Japan/China, and Europe, respectively. However, they have not gained approval from the U.S. FDA.…”
Section: Nitrogen Mustardsmentioning
confidence: 99%
“…For example, SarCNU 22 was designed by using N -methylglycinamide as a carrier and showed a good selectivity for cancer cells via the extraneuronal monoamine transporter (EMT) . Although SarCNU showed better efficacy than carmustine against gliomas, , it caused severe pulmonary toxicity in phase II trials and is not approved by the U.S. FDA. , Other compounds, including ranimustine 23 , nimustine 24 , and fotemustine 25 , are approved to be used in Japan, Japan/China, and Europe, respectively. However, they have not gained approval from the U.S. FDA …”
Section: Dna Alkylating Agents and Their Mechanisms Of Action In Form...mentioning
confidence: 99%
“…The National Cancer Institute supported several clinical trials to assess response rate, survival and effects of treatment, in malignant gliomas and metastatic colorectal cancer (Wong et al, 2006).…”
Section: Novel Nitrosourea Derivatives Of Clinical Interestmentioning
confidence: 99%